摘要
Non-alcoholic fatty liver disease (NAFLD) is regarded as a pandemic that affects about a quarter of the global population. Recently, host-gut microbiota metabolic interactions have emerged as distinct mechanistic pathways implicated in the development of NAFLD. Here, we report that a group of gut microbiota-modified bile acids (BAs), hyodeoxycholic acid (HDCA) species, are negatively correlated with the presence and severity of NAFLD. HDCA treatment has been shown to alleviate NAFLD in multiple mouse models by inhibiting intestinal farnesoid X receptor (FXR) and upregulating hepatic CYP7B1. Additionally, HDCA significantly increased abundances of probiotic species such as Parabacteroides distasonis, which enhances lipid catabolism through fatty acid-hepatic peroxisome proliferator-activated receptor alpha (PPAR alpha) signaling, which in turn upregulates hepatic FXR. These findings suggest that HDCA has therapeutic potential for treating NAFLD, with a unique mechanism of simultaneously activating hepatic CYP7B1 and PPAR alpha.
学科与关键词
- Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signalingPan, Linyu; Yu, Ze; Liang, Xiaolin; Yao, Jiyou; Fu, Yanfang; He, Xu; Ren, Xiaoling; Chen, Jiajia; Li, Xuejuan; Lu, Minqiang*; Lan, Tian*Hepatology Communications, 2023, 7(2): e0039.
- Equol, a metabolite of gut microbiota, attenuates liver steatosis via the SIRT1/HNF4α pathway in NAFLD miceLuo, Zhizhong; Yang, Ling; He, Jiqian; Han, Yi; Rong, Xianglu; Luo, Duosheng*; Guo, Jiao*Journal of Functional Foods, 2023, 107: 105640.
- Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered viewChen, Hui-Ting; Huang, Hong-Li; Li, Yong-Qiang; Xu, Hao-Ming; Zhou, Yong-Jian*WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26(16): 1901-1911.被引 30
